Safety of micronized palmitoylethanolamide (microPEA): lack of toxicity and genotoxic potential

Effect of Palmitoylethanolamide on Visual Field Damage Progression in Normal Tension Glaucoma Patients: Results of an Open-Label Six-Month Follow-Up

(2014) Ciro Costagliola et al.   JOURNAL OF MEDICINAL FOOD

Micronized/ultramicronized palmitoylethanolamide displays superior oral efficacy compared to nonmicronized palmitoylethanolamide in a rat model of inflammatory pain

(2014) Daniela Impellizzeri et al.   Journal of Neuroinflammation

Glia and Mast Cells as Targets for Palmitoylethanolamide, an Anti-inflammatory and Neuroprotective Lipid Mediator

(2013) Stephen D. Skaper et al.   MOLECULAR NEUROBIOLOGY

Palmitoylethanolamide, a naturally occurring disease-modifying agent in neuropathic pain

(2013) Stephen D. Skaper et al.   INFLAMMOPHARMACOLOGY

Palmitoylethanolamide Restores Myelinated-Fibre Function in Patients with Chemotherapy-Induced Painful Neuropathy

(2012) A. Truini et al.   CNS & Neurological Disorders-Drug Targets

Palmitoylethanolamide in the Treatment of Chronic Pain Caused by Different Etiopathogenesis

(2012) Antonio Gatti et al.   PAIN MEDICINE

Palmitoylethanolamide Effects on Intraocular Pressure After Nd:YAG Laser Iridotomy: An Experimental Clinical Study

(2011) Nicola Pescosolido et al.   JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS

Effect of palmitoylethanolamide–polydatin combination on chronic pelvic pain associated with endometriosis: Preliminary observations

(2010) Ugo Indraccolo et al.   European Journal of Obstetrics & Gynecology and Reproductive Biology

Misdiagnosed Chronic Pelvic Pain: Pudendal Neuralgia Responding to a Novel Use of Palmitoylethanolamide: Table 1

(2010) Rocco Salvatore Calabrò et al.   PAIN MEDICINE